Pulmonx AI Stock Analysis
Want to see LUNG full AI Analyst Report?
Pulmonx (LUNG) AI Stock Analysis
Pulmonx
(NASDAQ:LUNG)
The score is held back primarily by weak financial quality—ongoing losses, continued cash burn, and higher leverage despite strong revenue growth and high gross margins. Technicals are supportive with the stock trading above key moving averages and positive MACD. Earnings call commentary was constructive with reiterated revenue guidance, improving margins, and lower expected cash burn, but uncertainty around China timing and no 2027 guidance temper confidence; valuation is constrained by the negative P/E.
Pulmonx (LUNG) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $119.11M
- Dividend Yield
- ―
- Average Volume (3M)
- 631.79K
- Price to Earnings (P/E)
- -2.7
- Beta (1Y)
- 1.26
- Revenue Growth
- -3.15%
- EPS Growth
- 28.45%
- Country
- US
- Employees
- 296
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Pulmonx Business Overview & Revenue Model
Company Description
Pulmonx Corporation is a biomedical technology firm dedicated to developing and commercializing advanced, less invasive devices for managing chronic obstructive pulmonary diseases. Its primary offering, the Zephyr Endobronchial Valve, is specifically...
How the Company Makes Money
Pulmonx primarily makes money by selling its Zephyr Endobronchial Valve system for use in hospital-based bronchoscopic procedures. Revenue is generated mainly from: (1) sales of single-use Zephyr valves implanted during BLVR procedures (a recurring,...
Pulmonx Earnings Call Summary
The call was strongly constructive. Pulmonx returned to year-over-year revenue growth in both the U.S. and international businesses, improved gross margin, reduced operating expenses and losses, reiterated its full-year revenue outlook, and reported progress in its sales organization, clinical programs, China restart, and liquidity position. The main challenges were the relatively inexperienced salesforce, continued cash utilization and net losses, uncertainty around China's shipment timing, and the lack of 2027 guidance.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Pulmonx reiterated full year 2026 revenue guidance of $90 million to $92 million, now expects full year 2026 gross margin to be approximately 77%, operating expenses to fall between $108 million and $109 million, inclusive of approximately $14 million of noncash stock based compensation expense, and cash burn to be roughly $22 million, which would be a 30% reduction from our cash burn in 2025. Management expects year-over-year growth to continue for the remainder of the year, China shipments to resume by early next year, and CONVERT II IDE trial enrollment to be completed in the back half of next year; it expects AeriSeal to be commercial in Europe in 2027, with material revenues out of Europe with AeriSeal in 2028. Management said it is committed to sustaining double digit growth, expects OpEx to increase by maybe a few percent moving forward, expects to stay above 75% in terms of our gross margin profile, guides to about 40 a year in new accounts, and expects modest increases in the number of territories opportunistically.
Pulmonx Financial Statement Overview
Summary
Strong TTM revenue growth (~152%) and consistently high gross margins (~74–77%) are positives, and net margin is improving (TTM ~-48% vs. ~-60% in 2025). However, the company remains deeply unprofitable with ongoing operating losses, sustained cash burn (TTM operating/FCF about -$25.6M), and rising leverage as equity has declined (debt-to-equity ~1.65 in TTM).
Income Statement
34NegativeBalance Sheet
38NegativeCash Flow
27Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 88.78M | 90.50M | 83.79M | 68.67M | 53.66M | 48.42M |
| Gross Profit | 68.73M | 67.14M | 62.00M | 50.75M | 39.87M | 35.63M |
| EBITDA | -36.85M | -49.17M | -50.89M | -55.49M | -55.99M | -46.62M |
| Net Income | -42.55M | -54.00M | -56.39M | -60.84M | -58.92M | -48.66M |
Balance Sheet | ||||||
| Total Assets | 110.21M | 129.29M | 162.85M | 177.78M | 193.68M | 235.17M |
| Cash, Cash Equivalents and Short-Term Investments | 52.69M | 70.01M | 101.48M | 117.10M | 141.14M | 180.04M |
| Total Debt | 56.35M | 56.36M | 56.47M | 41.42M | 24.40M | 26.46M |
| Total Liabilities | 76.01M | 75.17M | 77.04M | 59.47M | 39.67M | 41.93M |
| Stockholders Equity | 34.20M | 54.12M | 85.81M | 118.31M | 154.01M | 193.24M |
Cash Flow | ||||||
| Free Cash Flow | -25.61M | -32.90M | -32.98M | -38.42M | -46.45M | -45.10M |
| Operating Cash Flow | -25.58M | -32.45M | -31.54M | -37.61M | -45.14M | -41.43M |
| Investing Cash Flow | -31.00K | 30.48M | 17.48M | -2.01M | -4.22M | -46.26M |
| Financing Cash Flow | 1.73M | 903.00K | 1.36M | 21.40M | 2.47M | 4.50M |
Pulmonx Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LUNG, the sentiment is Positive. The current price of 2.69 is above the 20-day moving average (MA) of 2.57, above the 50-day MA of 2.16, and above the 200-day MA of 1.72, indicating a bullish trend. The MACD of 0.22 indicates Negative momentum. The RSI at 57.36 is Neutral, neither overbought nor oversold. The STOCH value of 46.72 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LUNG.
Pulmonx Risk Analysis
Pulmonx disclosed 83 risk factors in its most recent earnings report. Pulmonx reported the most risks in the "Legal & Regulatory" category.
Latest Risks Added
3 New RisksPulmonx Peers Comparison
Overall Rating
LUNG54Neutral
APYX46Neutral
SRTS45Neutral
TELA44Neutral
ICCM41Neutral
XTNT39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 54Neutral | $119.11M | -2.69 | -98.23% | ― | -3.15% | 28.45% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 46Neutral | $104.89M | -12.59 | -70.78% | ― | 24.35% | 46.90% | |
| 45Neutral | $37.86M | -2.37 | -38.65% | ― | -53.33% | -429.93% | |
| 44Neutral | $34.44M | -1.05 | 425.91% | ― | 1.46% | 15.79% | |
| 41Neutral | $2.84M | -0.15 | -174.26% | ― | 31.80% | 27.37% | |
| 39Underperform | $28.82M | -1.76 | -36.21% | ― | -24.44% | -1012.80% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| LUNG | Pulmonx Corporation | 2.69 | 1.38 | 105.34% | |
| APYX | Apyx Medical | 2.49 | -1.55 | -38.37% | |
| XTNT | Xtant Medical Holdings Inc | 0.20 | -0.44 | -68.36% | |
| SRTS | Sensus Healthcare, Inc. | 2.30 | -1.63 | -41.48% | |
| TELA | Tela Bio, Inc. | 0.78 | -0.28 | -26.42% | |
| ICCM | Icecure Medical Ltd. | 1.03 | -18.44 | -94.71% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 04, 2026
